Article Text

Download PDFPDF
A mesalazine enema for ulcerative colitis
  • Relevant BNF section: 1.5

Abstract

Given by mouth, drugs based on 5-aminosalicylic acid (5-ASA) are often effective in inducing or maintaining remission in patients with ulcerative colitis.1 All of them depend on delaying the release of 5-ASA, so minimising its absorption in the small intestine and maximising delivery to the colon. With sulphasalazine (a chemical combination of 5-ASA and sulphapyridine) and olsalazine (a combination of two molecules of 5-ASA) cleavage of the azo bond by bacteria releases free 5-ASA in the colon. Oral formulations of mesalazine (the approved name for 5-ASA when given alone as a drug) use various physical mechanisms to release the 5-ASA gradually during transit through the gastrointestinal tract. Mesalazine can now be administered directly to the colon as an enema (Pentasa - Yamanouchi Pharma). How effective is this method of administering mesalazine and does it have a specific place in therapy?

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

  • Relevant BNF section: 1.5

View Full Text

Footnotes